Other formats:
BibTeX
LaTeX
RIS
@misc{2364740, author = {Demlová, Regina and Kubelová, Michaela}, address = {Brno}, edition = {NA}, keywords = {metastatic colorectal cancer; wild-type KRAS / NRAS; miR-31-5p; RASmiR; clinical study}, language = {eng}, location = {Brno}, publisher = {MU LF/MŠMT/MOÚ}, title = {DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023}, url = {https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001210-15/CZ}, year = {2023} }
TY - GEN ID - 2364740 AU - Demlová, Regina - Kubelová, Michaela PY - 2023 TI - DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023 VL - NA PB - MU LF/MŠMT/MOÚ CY - Brno KW - metastatic colorectal cancer KW - wild-type KRAS / NRAS KW - miR-31-5p KW - RASmiR KW - clinical study UR - https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001210-15/CZ N2 - Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR) Phase II. This is the fourth annual DSUR for the RASmiR trial summarising safety data received by the Sponsor from August 1, 2022 – July 31, 2023. Clinical trial RASmiR is a multicenter, open label, single-arm, phase II trial. During the period under review, 30 patients were enrolled to the study. ER -
DEMLOVÁ, Regina and Michaela KUBELOVÁ. \textit{DEVELOPMENT SAFETY UPDATE REPORT RASMIR 1.8.2022– 31.7.2023}. NA. Brno: MU LF/MŠMT/MOÚ, 2023, 16 pp. NA.
|